USFDA warns Cipla for lapses in manufacturing practices at Pithampur facility

​According to an exchange filing, the drug manufacturer was given a detailed breakdown of the lapses in methods followed at the facility ​by the USFDA. ​"This warning letter summarizes contraventions regarding methods or controls followed at the facility which do not conform to the prescribed cGMP regulations and contains directional guidance for necessary corrections," the filing said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hMxnKtl
via IFTTT